Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LGMN | Q99538 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25970628 | 0.86 | BRD4 (0.44) | BRD4HASPINMETHTR3ACHRNB2 | |
| SCHEMBL25970672 | 0.86 | HTR3A (0.44) | BRD4METHTR3A | |
| SCHEMBL21557651 | 0.83 | MAPK1 (0.32) | MAPK1LGMNCHRNB2CHRNA4POLB | |
| SCHEMBL13745998 | 0.83 | BRD4 (0.45) | BRD4METPOLBALDH1A1HSD17B10 | |
| SCHEMBL25970829 | 0.79 | BRD4 (0.42) | BRD4METMAPK1LRRK2POLB | |
| SCHEMBL25970635 | 0.78 | BRD4 (0.41) | BRD4HASPINMETALDH1A1 | |
| SCHEMBL25970639 | 0.78 | MET (0.42) | BRD4METMAPK1LGMNALDH1A1 | |
| SCHEMBL25970824 | 0.77 | BRD4 (0.45) | BRD4HASPINMAPK1LRRK2 | |
| SCHEMBL25970789 | 0.76 | BRD4 (0.43) | BRD4HASPIN | |
| SCHEMBL25970769 | 0.76 | BRD4 (0.43) | BRD4HASPINMETMAPK1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | BRD4 1103/4885HASPIN 975/4885MET 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.